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Abstract
Background: Target repurposing utilizes knowledge of ‘‘druggable’’ targets obtained in one organism and exploits this
information to pursue new potential drug targets in other organisms. Here we describe such studies to evaluate whether
inhibitors targeting the kinase domain of the mammalian Target of Rapamycin (mTOR) and human phosphoinositide-3-
kinases (PI3Ks) show promise against the kinetoplastid parasites Trypanosoma brucei, T. cruzi, Leishmania major, and L.
donovani. The genomes of trypanosomatids encode at least 12 proteins belonging to the PI3K protein superfamily, some of
which are unique to parasites. Moreover, the shared PI3Ks differ greatly in sequence from those of the human host, thereby
providing opportunities for selective inhibition.
Methodology/Principal Findings: We focused on 8 inhibitors targeting mTOR and/or PI3Ks selected from various stages of
pre-clinical and clinical development, and tested them against in vitro parasite cultures and in vivo models of infection.
Several inhibitors showed micromolar or better efficacy against these organisms in culture. One compound, NVP-BEZ235,
displayed sub-nanomolar potency, efficacy against cultured parasites, and an ability to clear parasitemia in an animal model
of T. brucei rhodesiense infection.
Conclusions/Significance: These studies strongly suggest that mammalian PI3/TOR kinase inhibitors are a productive
starting point for anti-trypanosomal drug discovery. Our data suggest that NVP-BEZ235, an advanced clinical candidate
against solid tumors, merits further investigation as an agent for treating African sleeping sickness.
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Introduction
The pathogenic protozoans Leishmania major, L. donovani,
Trypanosoma brucei, and T. cruzi are the causative agents for a
collection of diseases that primarily affect the developing world,
and are potentially lethal when untreated. Taken together, visceral
and cutaneous leishmaniases, human African trypanosomiasis
(HAT, or sleeping sickness) and Chagas disease affect over 22
million patients annually, causing nearly 100,000 deaths per year.
Transmitted by the bite of infected insects, these diseases are
treated by agents that are far from optimal in terms of safety,
efficacy, and dosing methods [1,2,3]. Resistance to many of these
therapies is emerging [4,5,6]. Since these diseases affect the
poorest parts of the world, there is little opportunity to recover
drug discovery research costs, and thus they are largely
‘‘neglected’’ by the biopharmaceutical industry.
The discovery of new therapeutic agents is expensive and time
consuming, and various strategies have been implemented in order
to mitigate costs and speed drug discovery [7]. While the
pharmaceutical industry frequently begins drug discovery pro-
grams with high-throughput screening and extended medicinal
chemistry research programs, this paradigm remains unaffordable
for most not-for-profit endeavors to implement. Therefore, the
approach of ‘‘target repurposing’’ is frequently employed, where
molecular targets in parasites are matched with homologous
human targets that have been previously pursued for drug
discovery [8,9,10,11]. In the best case, drugs that are selective
for these human targets will have been carried into human clinical
studies, strongly suggesting that the homologous parasite target is
likely ‘‘druggable’’ [12], that is, that compounds can be designed
to inhibit the target that are safe and orally bioavailable.
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With an eye towards target repurposing for anti-trypanosomal
drug discovery, we have identified the trypanosomal phosphoino-
sotide 3-kinases (PI3Ks) as a promising class of targets for pursuit.
In humans, inhibition of members of the PI3K family has attracted
significant interest as targets in the discovery of new anticancer
and anti-inflammatory agents [13,14,15]. This kinase family
provides critical control of cell growth and metabolism, and is
comprised of three classes (I–III), as determined by structure,
regulation, and substrate specificity. The Target of Rapamycin
(TOR) kinase (a member of the PI3K-related kinase (PKK)
subfamily) has received particular interest due to its central role in
fundamental processes such as growth, cell shape and autophagy.
The TOR kinases were first identified through inhibition studies
with the natural product rapamycin and related compounds. This
inhibition is now known to be mediated through interactions of the
TOR FKBP12-rapamycin-binding (FRB) domain with the
rapamycin-binding protein FKBP12 [16,17]. More recently,
inhibitors targeting the mammalian TOR (mTOR) kinase domain
have been developed [18,19,20,21,22,23]. In addition, significant
effort has been employed to discover inhibitors targeting specific
PI3K family members [24].
Thus far, while some agents show selectivity for mTOR or for
various specific PI3Ks, selectivity is rarely absolute. Many
inhibitors show broad activity against a spectrum of PI3K or
TOR family members. Nonetheless, both selective mTOR and
these so-called ‘‘mixed’’ PI3K inhibitor classes have shown
promise as cancer therapeutics, suggesting that absolute specificity
may not be required for therapeutic efficacy [25,26]. Some key
examples of these mTOR-selective and mixed inhibitors are
shown in Table 1 and Figure 1.
Database mining of trypanosomatid genomes has revealed the
presence of at least 12 proteins belonging to the PI3K protein
superfamily (PFAM PF00454), many of which are unique to the
parasites. Notably orthologous proteins are highly divergent from
those of the human host. These include predicted kinases related
to the eukaryotic class I and II PI3Ks, PI4Ks, and PIKKs
including TOR, ATM and ATR ([27,28], and data not shown).
Where tested, PI3Ks appear to be essential for viability and/or
virulence in trypanosomatids. Two PIK subfamily members have
been examined in T. brucei. The trypanosome Class III PI3K
TbVps34 has an essential function in membrane trafficking and in
Golgi segregation during cell division [29]. These authors
suggested that, similar to yeast, T. brucei possesses only one
genuine PI3K. TbPI4Kb is also an essential protein in T. brucei,
required for maintenance of Golgi structure, protein trafficking,
and cytokinesis [29]. Trypanosomatids possess four distinct genes
belonging to the TOR family, in contrast to mammals, which
possess a single mTOR protein [30,31,32,33]. TORs act in
concert with other proteins in complexes referred to as TORCs,
which have different protein subunit compositions, and cellular
functions [34].
In T. brucei, the two conserved signaling complexes, TORC1
and TORC2, whose functions appear analogous to that described
in mammalian or yeast TORCs, mediate the essential functions of
TOR1 and TOR2 for cell growth [33,35]. While TbTORC1
regulates protein synthesis, cell cycle progression and autophagy,
TbTORC2 plays a key role in maintaining the polarization of the
actin cytoskeleton, which is required for the proper functioning of
endocytic processes, cell division, and cytokinesis [30,36].
Correspondingly, TOR1 and TOR2 are essential genes in
Leishmania major [31]. Recent work has characterized a third
TOR protein, TOR3, in Leishmania major and T. brucei, that is
implicated in the formation of acidocalcisomes and participation
in stress response [31,32]. A fourth TOR in T. brucei and Leishmania
(TOR4) lacks the FRB domain responsible for binding rapamycin-
binding proteins, yet possesses all other characteristic domains of
TOR kinases [30,31].
The essentiality of several PIKs and TOR1 and TOR2 and the
requirement for TOR3 for virulence in both trypanosomes and
Leishmania provide genetic validation of these essential kinases as
potential drug targets. Since rapamycin analogs are relatively
modest inhibitors of trypanosomatid TORs and/or parasite
growth [30,31,37] and difficult to synthesize, we focused in this
work on kinase domain inhibitors under development. As these
kinase domain inhibitors are generally more drug-like, soluble, and
synthetically accessible than rapamycin analogs, we anticipate
these properties could facilitate future optimization efforts.
Materials and Methods
Ethics statement
The animal experimental protocol (2010102/1) used for African
trypanosome studies was reviewed and approved by the Ethical
Committee IPBLN-CSIC of the Spanish Council of Scientific
Research (CSIC). For T. cruzi, animal studies were approved by
the Institutional Animal Care and Use Committee of New York
University School of Medicine (protocol #81213), which is fully
accredited by the Association For Assessment and Accreditation
Of Laboratory Animal Care International (AAALAC). For L.
major, animal studies were approved by the Animal Studies
Committee at Washington University (protocol #20090086) in
accordance with the Office of Laboratory Animal Welfare’s
guidelines and AAALAC.
Inhibitor compounds
Inhibitor compounds were received from commercial vendors
and used as received. PI-130, NVP-BEZ235, Ku-0063794, Pp242,
and WYE-354 were obtained from Chemdea, Inc. (Ridgewood,
NJ). LY294002, LY303511, and Compound 401 were obtained
from Tocris Biosciences (Ellisville, MO).
Potency assessment against T. brucei
Assays were performed using the strain of T. brucei brucei Lister
427 adapted to the laboratory, and the human-infective strain T. b.
Author Summary
In our study we describe the potency of established
phosphoinositide-3-kinase (PI3K) and mammalian Target
of Rapamycin (mTOR) kinase inhibitors against three
trypanosomatid parasites: Trypanosoma brucei, T. cruzi,
and Leishmania sp., which are the causative agents for
African sleeping sickness, Chagas disease, and leishmani-
ases, respectively. We noted that these parasites and
humans express similar kinase enzymes. Since these similar
human targets have been pursued by the drug industry for
many years in the discovery of cellular growth and
proliferation inhibitors, compounds developed as human
anti-cancer agents should also have effect on inhibiting
growth and proliferation of the parasites. With that in
mind, we selected eight established PI3K and mTOR
inhibitors for profiling against these pathogens. Among
these inhibitors is an advanced clinical candidate against
cancer, NVP-BEZ235, which we demonstrate to be a highly
potent trypanocide in parasite cultures, and in a mouse
model of T. brucei infection. Additionally, we describe
observations of these inhibitors’ effects on parasite growth
and other cellular characteristics.
Effect of PI3K/mTOR Inhibitors on Trypanosomatids
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rhodesiense (EATRO3 ETat1.2 TREU164 [38]). Both strains were
grown and tested as bloodstream forms. To establish the EC50,
cultures of Trypanosoma brucei and T. b. rhodesiense were treated with
two-fold increasing concentrations of compounds (with similar
DMSO increasing concentration as control). We also utilized T. b.
gambiense strain Eliane MHOM/CI/52/ITMAP 2188, and
another T. b. brucei, strain 927/4 GUTat10.1 [38]. Cell
populations were measured at 72 hours with an Infinite F200
microplate reader (Tecan Austria GmbH, Austria); the determi-
nation of cell viability was carried out by the established
colorimetric technique AlamarBlueH with modifications, a 96-well
plate format spectrophotometric assay which measures the ability
of living cells to reduce resazurin [39,40]. Data obtained with T. b.
brucei Lister 427 were confirmed by manual counting in a
Table 1. Selectivity profile of the selected inhibitors against human enzymes.
Compound Inhibition of Cell Growth mTOR PI3K Refs.
p110a p110b p110d p110c
EC50 (mM) IC50 (mM) IC50 (mM) IC50 (mM) IC50 (mM) IC50 (mM)
NVP-BEZ235 0.05 ,0.01 0.004 0.075 0.007 0.005 [25,46,58]
PI-103 0.5 0.02 0.0036 0.003 0.25 [54,68]
LY294002 5 0.73 0.31 1.06 6.6 [69,70]
LY303511 1 [51]
Compound 401 1 5.3 .100 [56,71]
Pp242 0.04 0.008 2.8 2.2 0.1 1.3 [19,20]
WYE-354 0.03 0.004 1 [21]
Ku-63794 0.03 0.01 8.9 .30 .5 .30 [22,23]
doi:10.1371/journal.pntd.0001297.t001
Figure 1. Inhibitors selected for this study. These include that are (a) selective for the mTOR kinase domain, and (b) inhibit both mTOR and
human PI3Ks.
doi:10.1371/journal.pntd.0001297.g001
Effect of PI3K/mTOR Inhibitors on Trypanosomatids
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Neubauer chamber for a direct microscopic examination to rule
out multinucleated phenotypes that could mask the colorimetric
assays, as well as the subtraction of solvent background to dismiss a
potential solvent-derived fluorescence. Pentamidine was used as
drug control for potency comparison, and T. b. brucei Lister 927
strain was included in our experiments to evaluate the adaptation
to medium for the different strains as a variable condition.
Analysis of morphological and cell cycle alterations from
compound treatment in T. brucei
Flow cytometry was used to assess cell size and DNA content, to
reveal a G1 or G2 arrest and multinucleated cells. Briefly,
bloodstream cells of T. brucei brucei Lister 427 strain in early log
phase culture were treated with high dose (1 mM for PI-103, 2 mM
for WYE-354 and Pp242 and 100 nM for NVP-BEZ235) of
compounds for 16 hours, when the cells were pelleted and washed
to remove all traces of drug. After permeabilization with 1 mL
saponin (0.5 mg/mL final concentration), the culture was RNAse
treated for 30 minutes (10 mg/mL final concentration) and stained
with 20 mg/mL propidium iodide immediately before its acquisi-
tion in a FACscan cytometer. Cells incubated with equivalent
concentration of drug solvent (DMSO) were included in each
experiment as control population.
Potency assessment against T. cruzi
T. cruzi trypomastigotes from the Tulahuen strain stably
expressing the b-galactosidase gene [41] were obtained from the
supernatant of infected cultures of LLC-MK2 cells harvested
between days 5 and 7. To remove amastigotes, trypomastigotes
were allowed to swim out of the pellet of samples that had been
centrifuged for 7 min at 2500 rpm.
For measurement of intracellular replication, 56104 NIH/3T3
cells and 56104 trypomastigotes per well were seeded in 96-well
plates in DMEM supplemented with 2% FBS and Pen-Strep-Glut.
DMEM did not contain phenol red to avoid interference with the
assay absorbance readings at 590 nM. After 3 hours, compounds
were added to a final volume of 200 mL/well at the indicated
concentrations and mixed by pipetting. A 4 mM Amphotericin B
solution (Sigma-Aldrich) was used as positive control. After 4 days
of incubation at 37uC 5% CO2, 50 mL of PBS containing 0.5% of
NP40 and 100 mM chlorophenol red-b-D-galactoside (CPRG)
(Fluka) were added to each well. Plates were incubated at 37uC for
4 hours and absorbance was read at 590 nm.
For evaluation of extracellular survival, free trypomastigotes
were rinsed once and placed in 96-well plates at 100,000/well with
the compounds in a final volume of 200 mL of DMEM (without
phenol red) supplemented with 2% FBS, Pen-Strep-Glut and
100 mM CPRG. Plates were incubated for 24 h at 37uC and
absorbance was read at 590 nm.
Potency Assessment against Leishmania
Leishmania major strain FV1 (MHOM/IL/80/Friedlin) was
grown in M199 media [42]. Leishmania donovani strain LdBob
(MHOM/SD/62/1S-CL2D) were grown in modified M199
media as promastigotes (26uC) [43]. Amastigote specific media
(37uC) was used for growth and differentiation of amastigotes [43].
L. donovani axenic amastigotes were passed once following
differentiation prior to use. Cells were enumerated using a Coulter
Counter (BD Biosciences); as amastigotes tend to grow in clumps,
L. donovani axenic amastigotes were passed gently through a blunt
27-gauge needle prior to counting. For determination of EC50
values, log phase cells were inoculated at concentration of 105/ml
into appropriate media with compounds as indicated, and counted
when the controls lacking drug had reached late logarithmic
phase. The EC50 is defined as the concentration of drug inhibiting
50% of control growth, and was calculated by linear regression
analysis using SigmaPlot 2000.
Cell size and DNA content analysis in Leishmania
L. major log phase promastigotes were inoculated at a
concentration of 106 cells/ml into media with compounds as
indicated, and incubated overnight with varying drug concentra-
tions to assess cell size and DNA content. For cell size, forward
scatter of live promastigotes was measured by a FACS flow
cytometer (Becton Dickinson), utilizing dye exclusion with 5 mg/
ml propidium iodide (PI) to gate for live cells. DNA content was
determined by flow cytometry using fixed and permeabilized L.
major stained with PI as previously described [44,45], but reducing
the incubation time with PI and RNase A from 1 hour to
30 minutes. Histogram analysis was performed using CellQuest
3.1 software (BD Bioscience).
Drug dosage for in vivo experiments
The targeted dosage of inhibitors was determined based on the
pharmacokinetic studies disclosed by Maira, et al. [46]. Our goal
was to test NVP-BEZ235 in the animal models at the highest dose
achievable without inducing toxicity. For L. major, 12.5 mg/kg
orally was the highest tolerable dose while 30 mg/kg intraperito-
neally (ip) was used for the T. cruzi infections. A lower dose was
initially used in T. brucei, 5 or 10 mg/kg intraperitoneally.
In vivo drug evaluation in T. brucei
Female Balb/C mice (Jackson Laboratories, Bar Harbor, ME)
were infected with 104 cells of an early log phase culture of T. b.
rhodesiense EATRO3; 72 hours after infection the mice were
arbitrarily separated into three independent groups, daily treated
with 5 or 10 mg/kg NVP-BEZ235, 20 mg/kg pentamidine, or
DMSO, via intraperitoneal injection for four days. The parasit-
emia was checked at days 3, 5, 7, 11 and 14 post-infection in alive
mice: in those cases the parasitemia was too low to detect by
Neubauer chamber count, the extracted blood was incubated in a
24-well plate with HMI-9 medium supplemented with 20% SBFi
at 37uC with 5% CO2, and positive wells were confirmed by direct
visualization of parasites. Humanitarian sacrifice was executed,
according to Ethic Commission of Animal Welfare directions, and
necropsies were done in order to identify any physical side effect
related to administration.
In vivo drug evaluation in T. cruzi
Balb/c mice were inoculated intraperitoneally with 105
trypomastigotes from T. cruzi Y strain expressing firefly luciferase
(kindly provided by Dr. Barbara Burleigh, Harvard University).
On day 7 post infection, mice were anesthetized with ketamine/
xylazine and injected with 3 mg of D-Luciferin Potassium Salt
(Gold Biotechnology) at 20 mg/ml in PBS and imaged in the IVIS
Lumina II (Caliper Life Sciences). On day 8, groups of five mice
were injected intraperitoneally with either 30 mg/kg of NVP-
BEZ235 in DMSO or only DMSO, as control. Mice were treated
for 5 days and imaged again on day 13. Data is expressed as the
ratio between luciferase units in day 13 versus day 7 to determine
the progression of infection with and without drug treatment.
In vivo drug evaluation in L. major
Mice were infected with luciferase expressing L. major
(LmFV1LucTK-1) and analyzed by bioluminescent imaging as
described [47]. Balb/c mice were infected with 105 L. major
Effect of PI3K/mTOR Inhibitors on Trypanosomatids
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metacyclic stage parasites purified by gradient centrifugation [48].
Luminescence was measured using an IVIS 100 instrument and
analyzed with Living Image software version 2.60. NVP-BEZ235
was resuspended in DMSO and applied at 12.5 mg/kg/day by
oral gavage for 10 days, with treatment starting day 17 post
infection. At this dose the mice showed significant weight loss,
suggesting that this dosage was the highest practicable, as dosing
intraperitoneally at 25 mg/kg/day was lethal.
List of accession numbers
The following trypanosomatid enzymes are discussed in the
text: LmjF36.6320 (LmjTOR1), LmjF34.4530 (LmjTOR2),
LmjF34.3940 (LmjTOR3), LmjF20.1120 (LmjTOR4),
Tb927.8.6210 (TbVps34), Tb927.4.1140 (TbPI4K beta),
Tb927.3.4020 (TbPI4K alpha), Tb927.10.8420 (TbTOR1),
Tb927.4.420 (TbTOR2), Tb927.4.800 (TbTOR3) Tb927.1.1930
(TbTOR4), Tb11.01.6300 (TbATR), Tb927.2.2260 (TbATM).
Results
Compound selection
We selected eight commercially-available compounds
(Figure 1, Table 1) to profile for activity against Trypanosoma
brucei, T. cruzi and two species of Leishmania, cutaneous L. major and
visceral L. donovani. In order to identify potential inhibitors of
trypanosome TORs or PI3Ks, we selected a range of compounds
with varied potencies and selectivities against mTOR/PI3K. In
mammalian cells, compounds Ku-0063794 [22,23], Pp242 [19],
and WYE-354 [49] inhibit the kinase domain of mTOR selectively
with low nanomolar IC50 values. LY294002 is a mixed inhibitor
targeting both mTOR/PI3K [50], and many analogs have been
made (including LY303511, which inhibits mTOR-dependent and
independent pathways, but does not inhibit PI3Ks [51,52]). PI-103
inhibits PI3Ks with high potency and mTOR with a reported
20 nM IC50 [53,54,55]. Compound 401, a compound structurally
related to LY303511, inhibits mTOR and cellular growth at low
micromolar concentrations [56], while NVP-BEZ235 inhibits both
PI3Ks and mTOR with sub-nanomolar IC50 values [57,58].
In vitro testing of inhibitors
We first tested these compounds against parasites grown in vitro.
For T. brucei and Leishmania donovani, it is possible to cultivate free
parasites in vitro as the infective stage forms: bloodstream form
(BSF) for T. brucei, and axenic amastigotes for L. donovani.
Compounds were also tested against L. major promastigotes (the
stage carried normally by the insect vector). To study infective
forms of T. cruzi, compounds were added simultaneously with
trypomastigotes to 3T3 fibroblast host cells and incubated for four
days. This protocol thus monitors all steps of the T. cruzi infective
cycle (entry, differentiation and replication as amastigotes) as well
as potential effects mediated through host cell PI3Ks. The results
of the in vitro assessment of this inhibitor collection are shown in
Table 2.
The most potent compound against all the species tested was
NVP-BEZ235, showing nanomolar potency against BSF T. brucei
brucei (Lister 427) and sub-nanomolar activity (730 pM) against the
human-infective EATRO3 strain of T. b. rhodesiense (Figure 2A,
F). Interestingly, the BSF T. brucei gambiense, ELIANE strain [38]
was even more sensitive, with an EC50 of 179 pM. PI-103 showed
good activity against T. b. brucei and T. b. rhodesiense cultures (200
and 100 nM, respectively). The other inhibitors showed micro-
molar activity against T. brucei brucei, and, as observed with NVP-
BEZ235, these inhibitors are approximately ten-fold more potent
against T. b. rhodesiense. The variation in potency of NVP-BEZ235
across different strains of T. brucei, (including the T. brucei brucei
927/4 GUTat10.1 strain) is comparable to that seen in similar
studies of pentamidine, an established drug (Table 3).
In infections of host cell fibroblasts by infective trypomastigotes,
T. cruzi was refractory to all the inhibitors tested, except for NVP-
BEZ235 (EC50 = 120 nM, Figure 2E). For this compound
amastigotes lysis within host cells was observed after three days
when the drug was dosed at 350 nM (,36 the EC50; Figure 3A).
In contrast, NVP-BEZ235 showed little activity (EC50 .50 mM)
against free trypomastigotes, which do not replicate outside of host
cells. This suggests that NVP-BEZ235 could act specifically against
the amastigotes stage, or by activation of host cell responses.
For Leishmania, NVP-BEZ235 and PI-103 showed submicromo-
lar inhibition across both species and stages (70–140 or 320–
1050 nM respectively), while Pp242 and WYE-354 showed
modest activity (0.4–2.4 mM or 4–6 mM respectively, Figure 2B–
D). The remaining four inhibitors (LY294002, LY303511,
Compound 401 and Ku-63794) were inactive against L. major
promastigotes and L. donovani axenic amastigotes at the highest
concentration tested and were not tested against L. donovani
promastigotes. While some compounds showed statistically
significant differences amongst the Leishmania strains/species, the
differences were modest and not studied further.
Phenotypic effects elicited by PI3K inhibitor treatments
We examined effects of several of the strongest inhibitors on cell
size, shape and/or DNA content, since mTOR and PI3K
inhibitors affect the size of both mammalian and T. brucei cells
and induce characteristic growth phase arrests [30,59]. While
these studies cannot determine unambiguously which of the
numerous members of the trypanosomatid PI3K family may be
targeted, they provide a preliminary sense of the mode of action.
Indeed, the molecular target in each parasite may actually be
different.
Sixteen hour treatment of BSF T. brucei brucei with drug at an
effective concentration (described below) produced two different
types of effects on cellular DNA content (Figure 3B). Two drugs,
(PI-103 and Pp242, tested at 1 mM and 2 mM, respectively)
induced G1 arrest, an effect maintained even at low concentra-
tions of Pp242 (200 nM, data not shown). While the inhibitor PI-
103 showed a clearly defined profile in cell cycle progression,
NVP-BEZ235 produced a combination of effects on the cell cycle
progression at 0.1 mM, including the appearance of zoids
(anucleated cells) [60] and multinucleated cells. This relatively
high dose of NVP-BEZ235 (106 the EC50) produced a reduction
of G1 and G2 cells. Finally, treatment of T. b. brucei cells with
WYE-354 resulted in no significant variations in cell cycle, with a
small but noticeable reduction in cell size.
We examined the effect on cell size and DNA content for the
four compounds that displayed activity against L. major promas-
tigotes, using drug concentrations (EC60-EC90) that were strongly
inhibitory, but without inducing complete growth arrest or cellular
toxicity (as evidenced by PI exclusion tests, not shown). For all
concentrations tested, both PI-103 and WYE-354 treatment
induced a G1 arrest and a decrease in cell size (Figure 3C) as
seen for mTORC1 inhibitors in mammalian cells. In contrast,
NVP-BEZ235 treatment induced G2 growth arrest and increased
promastigote size in a manner similar to the cell phenotype
observed in mammalian cells exposed to mTORC2 inhibitors.
Microscopy data suggests that the G2 arrest was actually due to
altered cytokinesis, as evidenced by the abundance of individual
cells that contain 2 nuclei and kinetoplasts (data not shown), again
consistent with known effects of mTORC2 inhibition in
mammalian cells. Though PI-103, WYE-354 and NVP-BEZ235
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generated single phenotypes, Pp242 generated two different
phenotypes depending on the drug concentration. At lower
concentrations, Pp242 induced a decrease in cell size and a G1
arrest, while at higher concentrations a G2 arrest and increase in
cell size was observed (Figure 3C). This suggests the likelihood of
inhibition of multiple targets with various affinities within the
parasite.
In vivo tests
We chose the most active inhibitor, NVP-BEZ235, for testing in
appropriate animal models of T. brucei rhodesiense, T. cruzi, and L.
major infection. Using the highest tolerable doses appropriate for
each infection model, no efficacy was observed against either T.
cruzi (30 mg/kg, 5 days, intraperitoneal) or L. major (12.5 mg/kg/
day, 10 days, oral gavage) (data not shown). Weight loss was
observed in drug-treated mice infected with L. major and higher
drug doses were lethal.
In contrast, a marked decrease in parasitemia was observed by
intraperitoneal dosage (5 or 10 mg/kg) of NVP-BEZ235 in T.
brucei rhodesiense infected mice. Drug was administered once per
day, for four days. A dramatic decrease in parasitemia was
observed within two days, below the detection limit of 104
parasites/mL. All mice in the untreated group died the 6th day
post-inoculation, while the mean survival day (MSD) for animals
treated with 5 mg/kg of NVP-BEZ235 was extended to 10.8
(62.4) days. The MSD of mice treated with 10 mg/kg increased
to 13.4 (63.3) days, doubling the survival of the control group
(Figure 4). In comparison, parasitemia was below detectable
limits after two days of treatment with pentamidine (20 mg/kg, ip
[61]), and parasite counts remained below these limits for 30 days
past dosing (data not shown).
Discussion
The intent of these experiments was to identify promising small
molecules that could represent a starting point for further
medicinal chemistry optimization and a better understanding of
molecular pharmacology. Noting the functional and structural
homology between TOR and PI3Ks in humans and trypanoso-
matids and encouraged by the remarkable growth inhibitory
phenotype resulting from depletion of TOR in T. brucei [30] and L.
major [31], we identified and procured eight established inhibitors
for assessment against parasite cultures. Several of these inhibitors
inhibited parasite growth in all species/strains tested, and one,
NVP-BEZ235, reduced parasitemia in an animal model of T.
brucei rhodesiense infection, significantly extending survival. NVP-
BEZ235 showed very potent inhibition of T. brucei growth, with a
phenotype similar to that seen previously in genetic studies of TOR
[30] and TbVps34 [29]. A modest treatment regime (10 mg/kg,
for four days) was able to eliminate 80% of the parasites in T. b.
rhodesiense infections. The in vitro potency (179 pM EC50) observed
against T. b. gambiense was exceedingly high, at a level rarely seen
against these protozoan parasites. Given these encouraging results,
we believe that additional studies of NVP-BEZ235 are warranted
in the future, with the goal to determine whether an NVP-BEZ235
dosing regimen may be formulated able to achieve therapeutically
useful effects.
The reason for the difference in potency between T. b. rhodesiense
and gambiense, and between T. b. brucei Lister 427 and 927, is not
known at this time. (Table 3). T. b. gambiense, with a lower
generation rate and poorer adaptation to culture than T. b.
rhodesiense, may be more affected by an antiproliferative drug as
NVP-BEZ235. The potency of this compound and the complex
cell cycle phenotype observed suggest that the compound likely
has a number of molecular targets in T. brucei, perhaps affecting
other essential cellular functions besides cell proliferation.
T. cruzi was relatively insensitive to the inhibitors compared to
T. brucei. This may arise from the fact that T. cruzi trypomastigotes,
the form of the parasite that proliferates in the human, only
replicates in the intracellular environment. As a consequence,
compounds need to cross the plasma membrane of the host cell to
have access to T. cruzi, while T. brucei is directly accessible to the
drugs in the bloodstream. When NVP-BEZ235 was tested against
free, non-replicating T. cruzi trypomastigotes, it was inactive, while
it induced lysis of intracellular T. cruzi amastigotes. This raises the
possibility that this compound acts either specifically against the
amastigote stage, or through effects on host cell PI3Ks, or some
combination. The involvement of host cell PI3K and mTOR
pathways in immune evasion has been recently reported for L.
donovani [62].
Table 2. Summary of potency data of mTOR/PI3K inhibitors against trypanosomatid cultures.
Leishmania sp. Trypanosoma sp.
Compound L. majora L. donovani a L. donovani b T. cruzi c T. b. brucei d T. b. rhodesiense d
PI-103 0.3260.16 * 1.0560.28 0.6260.41 .25 0.21460.036 0.10560.01
NVP-BEZ235 0.1160.05 0.1460.08 0.0760.04 0.12 ,10 nM 0.7360.06 nM
LY294002 .25 - .5 - .2 -
LY303511 .25 - .5 .10 .2 -
Compd 401 .25 - .5 .10 .10 -
Pp242 2.460.8 # 0.4260.03 0.5060.09 .10 0.4860.1 0.16660.015
WYE-354 4.160.3* 5.9560.84 6.1061.73 .10 0.5860.26 0.7860.08
Ku-63794 .25 - .5 .10 0.8960.14 -
apromastigotes, average of three replicates;
baxenic amastigotes, average of three replicates;
ctrypomastigotes, average of three replicates, within 610.2%;
dbloodstream form, average of three replicates.
*p,0.05 for L. major vs. L. donovani promastigotes;
#p,0.05 for L. major promastigotes vs. L. donovani promastigotes or amastigotes.
Effective concentration (EC50) values are shown in micromolar concentrations except as noted.
doi:10.1371/journal.pntd.0001297.t002
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Leishmania showed a range of sensitivities to the panel of
inhibitors, with the most potent compounds active at sub-
micromolar concentrations. This may be compared to the efficacy
of current front line anti-leishmanial agents, whose potencies when
measured by methods similar to those described here range from
30 nM for amphotericin B to 15 mM for antimonial based
compounds [63].
The EC50 values for the compounds tested here were similar for
L. major promastigotes, L. donovani promastigotes and L. donovani
axenic amastigotes, suggesting that preliminary screening against a
Figure 2. Dose response curves of the most active inhibitors. PI-103, WYE-354, Pp242 and NVP-BEZ235 against (A) T. brucei rhodesiense, (B)
Leishmania donovani axenic amastigotes, (C) Leishmania donovani promastigotes, (D) Leishmania major promastigotes; (E), NVP-BEZ235 against T.
cruzi, and (F) T. brucei rhodesiense and gambiense.
doi:10.1371/journal.pntd.0001297.g002
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single form could be sufficient in the future. However, despite its
potency against L. donovani axenic amastigotes, high doses of NVP-
BEZ235 against L. major infections of mice showed no therapeutic
effect (data not shown). As discussed above for T. cruzi, the lack of
efficacy in the animal model of L. major could reflect a similar need
for the drug to traffic to the phagolysosomal compartment where
Leishmania reside. The 12.5 mg/kg oral dosing regimen tested here
resulted in severe weight loss (not shown) suggesting attempts to
treat with higher doses of NVP-BEZ235 would result in significant
toxicity.
Current data suggest there are at least 12 members of the PI3K
protein superfamily, for which the phenotypic effects of inhibition
or genetic deletion in T. brucei or Leishmania are known for only
five. Thus, it is difficult to assess from our studies what the likely
cellular target may be. However, with an eye towards initial
identification of specific targets potentially involved in the activity
of NVP-BEZ235, we note a similar cell cycle phenotype that Hall
et al. reported upon RNAi knockdown of TbVsp34 [29], including
the appearance of zoids, multinucleated cells and reduction of G1
and G2 (Figure 3B). Barquilla et al. also showed the same
phenotype after RNAi of TOR2 [36].
In trypanosomes and mammals, TORC1 inhibition is known to
result in G1 arrest and decreased cell size, while TORC2 results in
G2 arrest and increased cell size [30,34,64,65,66,67]. In both T.
brucei and Leishmania PI-103 resulted in G1 arrest and cell size
reduction, while NVP-BEZ235 resulted in aberrant cell cycle and
multiple cell sizes (Figure 3). WYE-354 also resulted in G1
arrest/cell size decrease in Leishmania. In contrast, while Pp242
showed G1 arrest/cell size decrease in trypanosomes, this was only
found at lower drug concentrations in L. major, and at higher drug
concentrations G2 arrest and increased cell size was observed
instead. Thus, while the effects of specific inhibitors on
trypanosomatids may resemble those seen against mammalian
cells targeting specific TOR or PI3K targets, future studies will be
required to more definitely establish the true mode(s) of action
against the individual parasite species, which may differ.
It appears that the mTOR/PI3K inhibitors display generally
superior activity against trypanosomatid growth over mTOR-
selective inhibitors. This may be suggestive of the effect being
mediated via inhibition of multiple trypanosomal PI3Ks, including
Table 3. Summary of potency data of NVP-BEZ235 against T.
brucei brucei, T. b. rhodesiense, and T. b. gambiense, compared
to the known drug pentamidine.
EC50 (nM)
NVP-BEZ235 Pentamidine
T. b. brucei 427 16.364.7 4.260.2
T. b. brucei 927 1.760.5 30.3610.4
T. b. rhodesiense EATRO3 0.7360.06 3.760.4
T. b. gambiense ELIANE 0.1860.2 2.560.5
doi:10.1371/journal.pntd.0001297.t003
Figure 3. Phenotypic observations of parasites upon dosage with NVP-BEZ235. (A) NIH-3T3 host cells were incubated with T. cruzi
trypomastigotes for 2 h before addition of NVP-BEZ235 (350 nM). Cells were incubated for 4 days during which time the parasites differentiate and
replicate as amastigotes. At that time cells were fixed and stained with an anti-T. cruzi antiserum (green) and DAPI to visualize DNA (blue). The upper
panel shows control cells with intact amastigotes, and the lower panel shows debris of parasite proteins throughout the host cell cytoplasm. (B,C)
Fluorescence-activated cell sorter (FACS) analysis of cell size (Forward Scatter, FSC) and DNA content after drug treatment. (B) Bloodstream form
culture of T. b. brucei was subjected to different drugs, indicated to the side, and analyzed by FACS for cell size and DNA content stained by
propidium iodide. Cell cultures were incubated during 16 h with PI-103 (1 mM), WYE-354 (2 mM), Pp242 (2 mM) and NVP-BEZ235 (0.1 mM), represented
with dark lines, and with DMSO as control population, represented as shaded area. (C) Treatment of Leishmania major promastigotes. Dark lines are
WT parasites examined when in logarithmic growth phase; shaded areas are parasites grown in the presence of the indicated concentration of drug.
Cell size (FSC) and DNA content (PI staining) were determined as indicated in Panel B and/or as described in the Methods. The subpanels show data
for PI-103 (4 mM, ,EC90); WYE-354 (25 mM, ,EC60); NVP-BEZ235 (0.5 mM, EC90) and Pp242 (dashed lines 12.5 mM/,EC90, shaded area 25 mM/,EC90).
doi:10.1371/journal.pntd.0001297.g003
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PKKs such as TOR. With that in mind, efforts to identify the
mechanism of action of these mTOR inhibitors in trypanosoma-
tids will direct further medicinal chemistry efforts. Despite the lack
of certainty of the mechanism of action of these compounds, the
results we report in this work provide a validation for the
repurposing approach as an efficient approach to identification of
compounds that can potentially be effective in parasite killing.
Conclusions
In summary, by application of the target repurposing approach,
we have identified a series of established mTOR and mTOR/
PI3K inhibitors that display a range of activity against the
trypanosomatid parasites T. brucei, T. cruzi, and Leishmania. These
compounds provide a promising starting point for discovery of
new drugs for trypanosomal infections. While additional study is
needed to determine the exact mechanism of action of these
agents, these results indicate promising inroads to a new class of
therapeutics. Encouragingly, the most potent and effective
compound identified in these studies, NVP-BEZ235, is in clinical
testing as an anticancer agent, and, if approved for this primary
indication, may also warrant exploration as an anti-trypanosomal
agent.
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